Evaluation of Occipital Nerve Stimulation in Intractable Occipital Neuralgias (StimO)

Evaluation of Occipital Nerve Stimulation in Intractable Occipital Neuralgias: a Multicentric, Controlled, Randomized Study

Medically intractable pain caused by occipital neuralgia can be very difficult to control with traditional pain management. Peripheral nerve stimulation which is used in migraines and cluster headache can be an alternative for these patients with occipital neuralgias when medical treatment and traditional pain management have failed (drugs for neuropathic pain, infiltrations, psychobehavioral approaches and multidisciplinary approach in a pain center). Occipital nerve stimulation consists to put a lead subcutaneously in front of the occipital nerve and to connect the lead to a pulse generator. A retrospective study of 60 patients was conducted in Nantes University Hospital. The results were good with the Visual Analog Scale (VAS) decreased from 8.4 preoperatively to 2.85 postoperatively. The medical quantification scale (MQS) was reduced to about 50% (18 preoperatively versus 9.9 postoperatively). Stimulation was quiet stable over time with a mean follow-up of 24 months (range 6 to 72 months). The aim of StimO is to confirm this result through a national controlled randomized multicenter study where occipital nerve stimulation will be compared to the optimal medical management.

Study Overview

• Status: Terminated
• Conditions: Occipital Neuralgia
• Intervention / Treatment: Device: Occipital nerve stimulation; Other: Optimal Medical Management

• Study Type: Interventional
• Enrollment (Actual): 22
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Caen, France, 14009
    • CHU de Caen
  • Clermont-Ferrand, France, 63003
    • CHU de Clermont-Ferrand
  • Colmar, France, 68024
    • Hôpitaux Civils de Colmar
  • Limoges, France, 87000
    • CHU Limoges
  • Lyon, France, 69003
    • Hôpital Pierre Wertheimer
  • Nantes, France, 44093
    • CHU de Nantes
  • Nice, France, 06001
    • CHU de Nice
  • Paris, France, 75475
    • Hopital Lariboisière
  • Paris, France, 92151
    • Hôpital Foch
  • Poitiers, France, 86021
    • Chu de Poitiers

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 81 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients between 18 and 85 years old
• Chronic occipital neuralgias as defined by International Headache Society (IHS) more than 6 months with permanent pain associated or not with paroxysm
• Secondary occipital neuralgias (post-traumatic, post-surgery, major arthrosis, compression or lesion of the occipital nerve …)
• Chronic neuropathic pain according to the Neuropathic Pain Diagnostic Questionnaire (DN4 ≥ 4)
• Maximum pain on VAS ≥ 50/100
• Failure of medical treatment (association of neuropathic medication like antiepileptic and/or antidepressant and/or antalgic treatment like paracetamol, tramadol or morphine) and pain management in a pain Unit including multidisciplinary approach, physiotherapy, block test in C1-C2, radiofrequency rhizolysis, and/or corticosteroid infiltration of C2 according to the criteria defined by Health Authorities for spinal cord stimulation.
• Reduction of pain with Transcutaneous Electrical Nerve Stimulation (TENS) in occipital area
• Neurological examen has to be completed and must be normal except for the occipital neuralgia territory
• A negative pregnancy test for women with childbearing potential
• Women of childbearing potential must use appropriate method(s) of contraception during the clinical trial
• Patients must be capable of giving informed consent and must have signed informed consent
• Affiliation to an appropriate health insurance

Exclusion Criteria:

• Contraindication to the experimental medical devices
• Titanium related allergies
• Patients with contraindications to general anesthesia
• Complete anaesthesia in the C2/Great occipital nerve territory
• Drug or alcohol addiction
• Psychiatric disorders (psychiatric evaluation)
• Any medical or psychological problems which may interfere with a smooth conduction of the study protocol (e.g. cancer with a limited life expectancy)
• Need for intensive nursing care
• Difficulty in follow-up
• Pregnant or lactating women
• Women not using contraception
• Adults under a legal protection regime (guardianship, trusteeship, "sauvegarde de justice")
• Exclusion period for another study
• Simultaneous participation in another clinical trial except if that other trial does not affect the StimO study as approved and documented by the sponsor

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Occipital Nerve Stimulation (ONS); Occipital nerve stimulation with percutaneous or surgical lead plus optimal medical management	Device: Occipital nerve stimulation; Occipital nerve stimulation with percutaneous or surgical lead; Other: Optimal Medical Management; Optimal Medical Management according to what is done in routine clinical practice : drug, psychobehavioral approach, acupuncture, sophrology, etc.
Active Comparator: Optimal Medical Management (OMM); Optimal Medical Management according to what is done in routine clinical practice	Other: Optimal Medical Management; Optimal Medical Management according to what is done in routine clinical practice : drug, psychobehavioral approach, acupuncture, sophrology, etc.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Efficacy of occipital nerve stimulation	Compare the decrease of pain (evaluated by visual analogic scale) after 6 months of treatment between the 2 groups (ONS / OMM)	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Decrease of medical treatment (i.e. decrease of Medication Quantification Scale (MQS) score) in the ONS group at 3 months	Evaluate the decrease of medical treatment (i.e. decrease of Medication Quantification Scale (MQS) score) after 3 months of occipital nerve stimulation in the ONS group	3 months
Decrease of medical treatment (i.e. decrease of Medication Quantification Scale (MQS) score) in the ONS group at 6 months	Evaluate the decrease of medical treatment (i.e. decrease of Medication Quantification Scale (MQS) score) after 6 months of occipital nerve stimulation in the ONS group	6 months
Maximum pain (using Visual Analogic Scale)	Comparison of maximum pain (using Visual Analogic Scale) between the 2 groups (ONS/OMM)	Up to 6 months
Average pain (using Visual Analogic Scale)	Comparison of average pain (using Visual Analogic Scale) between the 2 groups (ONS/OMM)	Up to 6 months
Relative decrease of pain (using Visual Analogic Scale) at 3 months	Comparison of the relative decrease of pain (using Visual Analogic Scale) at 3 months between the 2 groups (ONS/OMM)	3 months
Relative decrease of pain (using Visual Analogic Scale) at 6 months	Comparison of the relative decrease of pain (using Visual Analogic Scale) at 6 months between the 2 groups (ONS/OMM)	6 months
Efficacy of the treatment (using Migraine Disability Assessment (MIDAS) Test) at 3 months	Comparison of the efficacy of the treatment (using Migraine Disability Assessment (MIDAS) Test) at 3 months between the 2 groups (ONS/OMM)	3 months
Efficacy of the treatment (using Migraine Disability Assessment (MIDAS) Test) at 6 months	Comparison of the efficacy of the treatment (using Migraine Disability Assessment (MIDAS) Test) at 6 months between the 2 groups (ONS/OMM)	6 months
Quality of life (using EQ-5D-5L questionnaire)	Comparison of the quality of life (using EQ-5D-5L questionnaire) between the 2 groups (ONS/OMM)	Up to 6 months
Quality of life (using Hamilton Anxiety and Depression (HAD) scale)	Comparison of the quality of life (using Hamilton Anxiety and Depression (HAD) scale) between the 2 groups (ONS/OMM)	Up to 6 months

Collaborators and Investigators

• Sponsor: Nantes University Hospital

Study record dates

Study Major Dates

• Study Start (Actual): April 20, 2018
• Primary Completion (Actual): June 26, 2021
• Study Completion (Actual): September 3, 2021

Study Registration Dates

• First Submitted: March 16, 2018
• First Submitted That Met QC Criteria: March 22, 2018
• First Posted (Actual): March 23, 2018

Study Record Updates

• Last Update Posted (Actual): October 11, 2021
• Last Update Submitted That Met QC Criteria: October 4, 2021
• Last Verified: October 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Pain; Neurologic Manifestations; Neuromuscular Diseases; Peripheral Nervous System Diseases; Neuralgia
• Other Study ID Numbers: RC17_0013

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No